Literature DB >> 16378678

Anaplastic oligodendroglioma and gliomatosis type 2 in interferon-beta treated multiple sclerosis patients. Report of two cases.

Sasa Sega1, Alenka Horvat, Mara Popovic.   

Abstract

The concurrence of multiple sclerosis (MS) and brain tumors has been reported, but it is not known whether MS patients are at greater risk of harbouring the latter. The most common cerebral neoplasms reported in MS patients were oligodendroglioma, astrocytoma, glioblastoma and gliomatosis. MS can also present as a mass lesion that mimics a brain tumor. To establish the correct diagnosis radiological follow-up and/or histological confirmation is needed. Two cases of coincidental MS and brain tumors are reviewed. One is a 26-year-old woman with relapsing-remitting MS and an anaplastic oligodendroglioma, the other a 49-year-old woman patient with relapsing-remitting MS and gliomatosis type 2. Both patients were treated with interferon-beta1b and both died from the tumor. The concurrence of MS and brain tumors could be purely coincidental, or the result of neoplastic transformation of reactive glial cells in the areas of demyelination. The combination of a brain tumor and MS, and interferon-beta treatment could also be pure coincidence or an unknown side effect of treatment. Although interferon-beta has been said to function as a tumor-suppressor protein, the influence of long-term treatment of MS patients on cancer development is not known.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16378678     DOI: 10.1016/j.clineuro.2005.11.015

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  9 in total

1.  A case of oligodendroglioma and multiple sclerosis: Occam's razor or Hickam's dictum?

Authors:  Afsaneh Shirani; Gregory F Wu; Caterina Giannini; Anne H Cross
Journal:  BMJ Case Rep       Date:  2018-06-28

2.  Medulloblastoma and gliomatosis cerebri: rare brain tumors in multiple sclerosis patients.

Authors:  Ana Alexandra Duarte Martins da Silva; Sara Marta Pereira dos Santos Cavaco; Ricardo Jorge Ferreira Taipa; Pedro Ricardo Soares Pinto; Manuel Jorge Rocha Melo Pires
Journal:  Neurol Sci       Date:  2011-01-14       Impact factor: 3.307

3.  Genetic characterization of gliomas arising in patients with multiple sclerosis.

Authors:  Adam Khalil; Hilary Serracino; Denise M Damek; Douglas Ney; Kevin O Lillehei; B K Kleinschmidt-DeMasters
Journal:  J Neurooncol       Date:  2012-05-01       Impact factor: 4.130

Review 4.  Tumefactive demyelinating lesions: nine cases and a review of the literature.

Authors:  Lei Xia; Song Lin; Zhong-cheng Wang; Shao-wu Li; Li Xu; Jing Wu; Shu-yu Hao; Chuan-chuan Gao
Journal:  Neurosurg Rev       Date:  2009-01-27       Impact factor: 3.042

5.  Glioblastoma in multiple sclerosis: a case report.

Authors:  Giovanni Frisullo; Agata Katia Patanella; Viviana Nociti; Alessandro Cianfoni; Raffaele Iorio; Assunta Bianco; Alessandro Marti; Pietro Attilio Tonali; Anna Paola Batocchi
Journal:  J Neurooncol       Date:  2009-02-13       Impact factor: 4.130

Review 6.  Tumefactive Demyelinating Lesions in Multiple Sclerosis and Associated Disorders.

Authors:  Meredith C Frederick; Michelle H Cameron
Journal:  Curr Neurol Neurosci Rep       Date:  2016-03       Impact factor: 5.081

Review 7.  Concurrence of multiple sclerosis and brain tumors.

Authors:  Domenico Plantone; Rosaria Renna; Emilia Sbardella; Tatiana Koudriavtseva
Journal:  Front Neurol       Date:  2015-03-04       Impact factor: 4.003

8.  When tumefactive demyelination is truly a tumor: case report of a radiographic misdiagnosis.

Authors:  Breanna Taylor; Mallika P Patel; Katherine B Peters
Journal:  CNS Oncol       Date:  2021-01-15

9.  A challenging case of concurrent multiple sclerosis and anaplastic astrocytoma.

Authors:  Georges Sinclair; Yahya Al-Saffar; Philippa Johnstone; Mustafa Aziz Hatiboglu; Alia Shamikh
Journal:  Surg Neurol Int       Date:  2019-08-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.